Back to Journals » Infection and Drug Resistance » Volume 3

Clinical perspective on aztreonam lysine for inhalation in patients with cystic fibrosis

Authors Daddario MK, Hagerman J, Klepser ME

Published 28 October 2010 Volume 2010:3 Pages 123—132

DOI https://doi.org/10.2147/IDR.S7838

Review by Single-blind

Peer reviewer comments 6

Martha K Daddario1, Jennifer K Hagerman2, Michael E Klepser2

1Spectrum Health, Grand Rapids, Michigan; 2Ferris State University College of Pharmacy, Kalamazoo, Michigan, USA
Abstract: Progressive obstructive lung disease is a characteristic component of cystic fibrosis (CF). It is the pulmonary manifestations, including obstruction and endobronchial infection, which directly contribute to the premature mortality of patients affected with CF. Due to the devastating effects on the pulmonary system, interest abounds in ways to improve antimicrobial delivery to the lungs and to impact clinical patient outcomes positively, whilst minimizing systemic toxicities. Recently, aztreonam lysine for inhalation solution, a new monobactam formulation, was approved by the US Food and Drug Administration for use in a subgroup of CF patients with Pseudomonas aeruginosa to improve respiratory symptoms. The purpose of this review is to present a summary of relevant pharmacologic, microbiologic, and clinical data related to the use of aztreonam lysine for inhalation in patients with CF.

Keywords: aztreonam, cystic fibrosis, inhaled, aerosolized, antibiotic, Pseudomonas aeruginosa

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]